Study on the role of copidogrel in preventing celebral infarction after TIA
Objective To observe the effect of Clopidogrel combined with Xuezhikang on preventing cerebral infarction after transient ischemic attack (TIA). Methods 116 TIA patients in the Shangluo central hospital from January 2014 to December 2014 were randomly divided into two groups, all patients were given routine treatment, while 58 cases in the control group were given Clopidogrel 75mg, 1/d; 58 cases in the observation group were given 0.6 g Xuezhikang capsul based on the control group, twice one day; the course of treatment was 6 months. Before treatment and at the end of the course examination, blood samples were collected to test blood lipid, prothrombin time (PT), platelet count (PLT), activated partial thromboplastin time (APTT), ultrasound examination of carotid artery intima-media thickness (IMT), and the area of atherosclerotic plaque; after 12 months of follow-up, IMT and cerebral infarction and other cerebral vascular events of two groups were recorded in the 12 months after TIA. Results After treatment, the TG, TC and LDL-C in the observation group were significantly lower than that in the control group, and the HDL-C was significantly higher than that in the control group (P<0.05). MT and plaque area were significantly lower than those in the control group (P<0.05). 12 months after TIA, there were no obvious changes in liver and kidney function and blood routine in the two groups before and after treatment. There were no cases of skin, mucous membrane, intracranial or visceral hemorrhage. Conclusion Clopidogrel combined with Xuezhikang could effectively lower blood lipid.
NETL
NSTL
万方数据
维普
